COVID-19 vaccine effectiveness against severe disease from SARS-CoV-2 Omicron BA.1 and BA.2 subvariants - surveillance results from southern Sweden, December 2021 to March 2022.

Authors :: Björk J
Bonander C
Moghaddassi M
Rasmussen M
Malmqvist U
Inghammar M
Kahn F
Source :: Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin [Euro Surveill] 2022 May; Vol. 27 (18).
Publication Year :: 2022
Abstract: We compared vaccine effectiveness against severe COVID-19 between December 2021 and March 2022 when Omicron BA.1 and BA.2 were the dominating SARS-CoV-2 variants in Scania county, Sweden. Effectiveness remained above 80% after the transition from BA.1 to BA.2 among people with at least three vaccine doses but the point estimate decreased markedly to 54% among those with only two doses. Protection from prior infection was also lower after the transition to BA.2. Booster vaccination seems necessary to maintain sufficient protection.

Subjects :: COVID-19 Vaccines
Humans
Sweden epidemiology
Vaccine Efficacy
COVID-19 epidemiology
COVID-19 prevention & control
SARS-CoV-2

Language :: English
ISSN :: 1560-7917
Volume :: 27
Issue :: 18
Database :: MEDLINE
Journal :: Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin
Publication Type :: Academic Journal
Accession number :: 35514304
Full Text :: https://doi.org/10.2807/1560-7917.ES.2022.27.18.2200322

Full Text Access

Tools